Abstract Morbidity and mortality of breast cancer patients are drastically increased when primary tumor cells are able to spread to distant sites and proliferate to become secondary lesions. Effective treatment of metastatic disease has been limited; therefore, an increased molecular understanding to identify biomarkers and therapeutic targets is needed. Breast cancer metastasis suppressor 1 (BRMS1) suppresses development of pulmonary metastases when expressed in a variety of cancer types, including metastatic mammary carcinoma. Little is known of Brms1 function throughout the initiation and progression of mammary carcinoma. The goal of this study was to investigate mechanisms of Brms1-mediated metastasis suppression in transgenic mice that express Brms1 using polyoma middle T oncogene-induced models. Brms1 expression did not significantly alter growth of the primary tumors. When expressed ubiquitously using a b-actin promoter, Brms1 suppressed pulmonary metastasis and promoted apoptosis of tumor cells located in the lungs but not in the mammary glands. Surprisingly, selective expression of Brms1 in the mammary gland using the MMTV promoter did not significantly block metastasis nor did it promote apoptosis in the mammary glands or lung, despite MMTV-induced expression within the lungs. These results strongly suggest that cell type-specific over-expression of Brms1 is important for Brms1-mediated metastasis suppression.
Introduction
Metastasis is the most lethal attribute of breast cancers. Metastases are typically inoperable, difficult to target for treatment, and directly contribute to increased morbidity and mortality of breast cancer. Continuous improvements in early detection methods and treatments have contributed to 5-year breast cancer survival rates approaching 100%. However, survival rates are drastically reduced below 25% upon development of distant metastases [1] . An improved understanding of the molecular mechanisms of metastasis is necessary for identification of novel treatment strategies. In recent years there has been an increasing appreciation for metastasis suppressors which have provided necessary tools to dissect the molecular underpinnings of metastasis [2, 3] . Breast cancer metastasis suppressor 1 (BRMS1) significantly reduces lung metastases in athymic mice when expression is ectopically restored in human metastatic cell lines from breast [4] , melanoma [5] , ovarian [6] , and non-small cell lung carcinomas [7] . BRMS1 alters multiple cellular pathways involved in metastasis including: gap junctional intercellular communication [7] [8] [9] [10] , phosphoinositide pools and signaling [11, 12] , modification of nuclear factor kappa B (NFjB) signaling [13] [14] [15] , and cellular motility and invasion [5, 6, 15, 16] . In addition to these changes, Phadke et al. [17] demonstrated that BRMS1 expression decreased disseminated tumor cell viability and cell seeding in vivo, phenomena consistent with in vitro activation of pro-apoptotic signaling via caspase 3 and PARP cleavage.
Mediation of these pathways is likely attributed to BRMS1-regulated gene transcription via BRMS1 interactions with SIN3: histone deacetylase (HDAC) chromatin remodeling complexes through direct interaction with ATrich interacting domain 4A (ARID4A) and suppressor of defective silencing 3 (SUDS3) [18, 19] . Although there is no evidence of BRMS1 functioning as a transcription factor, BRMS1 has been shown to recruit HDAC1, and presumably SIN3 complexes, to NFjB consensus regions leading to inhibition of NFjB activity [15, 20] .
BRMS1 orthologs are highly conserved across many species. Especially pertinent to this study, the amino acid sequence of murine Brms1 is 95% homologous with human BRMS1 [21] . When re-expressed in 4T1 or 66cl4 metastatic mammary carcinoma cells, Brms1 significantly reduced metastases to the lungs in syngeneic BALB/c mice [22] . Furthermore, murine Brms1 associates with HDAC1 affirming functional similarity to human BRMS1, warranting its use in genetically-engineered mice to further investigate mechanisms of action in metastasis suppression.
Although restoration-of-expression experiments have been useful in xenograft and syngeneic models, these experimental systems do not fully recapitulate initiation and progression of malignancy and host-tumor interactions that occur throughout tumor progression [23, 24] . Development of Brms1 metastasis models in which tumors arise de novo and spontaneously metastasize (by utilizing geneticallyengineered mice) provides new insight into mechanisms of metastasis suppression. We developed two transgenic mouse models which over-express Brms1. The first, Brms1
MMTV , selectively expresses Brms1 in mammary glands using the mouse mammary tumor virus (MMTV) promoter. In the second, Brms1
Ubqs , Brms1 is expressed ubiquitously using the cytomegalovirus (CMV)-enhanced chicken beta actin promoter. Both models were used to test the impact of Brms1 over-expression on primary tumor development and metastatic potential by crossing them with the well-characterized polyoma middle T (PyMT) oncogene mammary tumor mouse model [25, 26] . As predicted, Brms1 function as a metastasis suppressor was affirmed in the Brms1
Ubqs 9 MMTV-PyMT F 1 mice. Surprisingly, F 1 generation mice from Brms1 MMTV 9 MMTV-PyMT still developed metastases at similar levels to PyMT mice. These results reveal a more complex mode of action for Brms1-mediated metastasis suppression than was previously recognized.
Materials and methods

Mouse husbandry and analysis
All animal studies were carried out under the approval of the University of Alabama at Birmingham (UAB) Institutional Animal Care and Use Committee (IACUC). For mammary-selective expression of Brms1 cDNA, the 8.4 kb pMAMneo mammalian expression vector which contains the RSV-LTR enhancer linked to the MMTV-LTR promoter was utilized. The vector contains the RSV-LTR enhancer linked to the MMTV-LTR promoter. The ubiquitous Brms1 expresser (Brms1 Ubqs ) expresses Brms1 in most tissues by the CMV-enhanced chicken b-actin promoter (CAG promoter). To generate Brms1
Ubqs mice, the pCX expression vector carrying the CAG promoter (a combination of the CMV early enhancer element and chicken b-actin promoter) was utilized. All pronuclear injections were performed by the UAB Transgenic Core and resulting chimera were mated with wild-type C57BL/6 mice resulting in heterozygous Brms1 transgenic mice. PyMT oncogene transgenic mice were obtained from Jackson Laboratories (Bar Harbor, ME).
All mice were tail-clipped, weaned (at *3 weeks), and genotyped. Transgenic Brms1 mice were genotyped by PCR using the following primers: GCCAAACTGAGTCAGAG GAG and GTGTTGTTTGGCTCCCTG. Transgene presence was identified by the presence of two genetic bands, one 720 bp endogenous Brms1 band and a 275 bp Brms1 cDNA band. PyMT mice were genotyped by PCR using the following primers: AACGGCGGAGCGAGGAACTG and ATCGGGCTCAGCAACACAAG. Transgenic mice were identified by the presence of a 556 bp genetic band. To validate increased Brms1 expression, normal mammary gland and lung tissues from transgenic Brms1 mice were collected, flash-frozen using liquid nitrogen, and expression was analyzed using real-time quantitative reverse transcription PCR (RT-qPCR).
Because Mice were monitored daily and incidence of the first tumor appearance was recorded. Body weight and total tumor burden were determined at necropsy. Normal mammary glands and mammary tumors were flash-frozen using liquid nitrogen for gene and protein analyses. In addition, aliquots of tumor tissue were formalin-fixed and paraffin-embedded for histological analyses. Tissues were processed, sectioned and either stained with hematoxylin and eosin or utilized for immunohistochemical assays. Lungs were dissected and fixed in either Bouin's fixative or formalin-fixed and paraffin-embedded for histology. The number of lung metastases was counted by visual inspection of fixed lungs and by histological analysis. The number of macroscopic metastases in PyMT ?/-/Brms1 tg/wt was compared to control mice (PyMT ?/-/Brms1 wt ) to determine changes in metastatic potential that occurred due to Brms1 over-expression. Liver, spleen, and kidney were also collected and analyzed for the presence of metastases in other organs in addition to the lungs. When possible, littermates were compared as described above.
Real-time quantitative reverse-transcription PCR Flash-frozen tissue was homogenized by mortar and pestle and lysed with Qiazol Lysis Reagent (Qiagen, Valencia, CA). RNA was isolated using the miRNEasy extraction kit (Qiagen) according to the manufacturer's protocol, reversetranscribed and quantified using the miScript SYBR Green PCR kit (Qiagen) and Brms1-specific Quantitect Assay primers (Qiagen). Relative RNA expression in all samples was normalized to 18s rRNA expression levels and foldchange was calculated as previously described [27] .
Immunohistochemistry
For immunohistochemical analyses of proliferation and microvessel density, 5 lm thick sections of formalin-fixed, paraffin-embedded mammary tumor tissue sections were deparaffinized in xylene and rehydrated in graded alcohols. For antigen retrieval, slides were immersed and boiled for 20 min in a diluted (1:30), pH 9.0, antigen unmasking solution (Vector Laboratories, Burlingame, CA). Slides were incubated in a horse serum blocking solution (ImmPRESS system, Vector Laboratories) for 1 h followed by incubation with either Ki67 primary monoclonal antibody (Clone TEC3 Antigen, 1:100 dilution, Dako, Carpinteria, CA) or CD31 primary polyclonal antibody (Ab28364, 1:100 dilution, AbCam, Cambridge, MA) in phosphate-buffered saline solution containing 1% bovine serum albumin. Appropriate secondary antibody (ImmPRESS, Vector Laboratories) was applied and slides were incubated in DAB (3, 3 0 -diaminobenzidine) peroxidase substrate solution (Dako). Each slide was then incubated with Harris hematoxylin counterstain (Fisher Scientific, Waltham, MA). Nuclei of cells positive for Ki67 stained brown and the percentage of positive cells per high powered microscopic field was determined. A minimum of 1,000 cells were counted for each mammary tumor sample. Intratumoral microvascular density (iMVD) was determined by averaging the number of CD31-positive vessels in representative areas with the highest microvessel density (designated ''hot spots'') as previously described [28] . A minimum of three ''hot spots'' were counted per sample. To assess iMVD in metastases, the total number of CD31-positive vessels was counted per metastatic lesion per sample. Only lesions containing more than 500 cells were assessed for iMVD to analyze changes in angiogenesis due to potentially hypoxic conditions.
For analyses of apoptosis in tumor and lung tissue, the ApopTag Plus Peroxidase In Situ Apoptosis Detection Kit (Millipore, Billerica, MA) was utilized according to the manufacturer's protocol. Apoptotic bodies/nuclei were stained brown with DAB peroxidase substrate and the percentage of positive cells within the primary tumor per high powered microscopic field was determined as described above. The percentage of total positive cells per metastatic lesion was determined.
Statistical analysis
Continuous parameters were compared by the student's t test for body weight, age at necropsy, and number of metastases when controlling for age. The primary endpoint of interest was the number of visible lung macroscopic metastases in each genotype group. Due to a non-normal distribution, the median test was used to compare the total number of lung metastases per group. Because metastatic potential correlates with total tumor burden in PyMT mice, a multivariable analysis for number of lung metastases was conducted using generalized Poisson regression. Age was used as an offset variable in the multivariable model because some of the animals were euthanized early due to high tumor burden which may have affected the number of metastases. Tumor latency was calculated as the percentage of tumor-free mice throughout the study using KaplanMeier analyses. Data from tumor latency studies were analyzed by non-parametric Wilcoxon rank sum test. Tumor burden, proliferation, and apoptosis studies were analyzed by two-sample paired student's t test assuming equal variance. All analyses were performed using SAS (Ver. 9.2 Ò ) statistical analysis software. A P value \0.05 was deemed statistically significant.
Results
Brms1 expression is increased in transgenic mice
To validate increased Brms1 expression, RT-qPCR analysis was performed on normal mammary gland and lung tissues from ubiquitous and mammary-selective transgenic Brms1 mice. Both Brms1 MMTV (P = 0.31) and Brms1
Ubqs mice (P = 0.01) exhibited an increase of Brms1 expression in mammary gland compared to wild-type C57BL/6 mice (Fig. 1a) . Although Brms1 should be over-expressed in all tissues in Brms1 Ubqs mice, we focused on expression in the major tissues involved in the PyMT mammary tumor model-mammary glands and lungs. As expected, Brms1 expression in lungs of Brms1
Ubqs mice was five times greater than observed in wild-type mice (P = 0.02) (Fig. 1b) . Brms1 was also increased in lung tissue of Brms1 MMTV mice (P = 0.04), confirming previous reports of ''leaky'' expression of the MMTV promoter [29] .
Increased Brms1 expression does not significantly alter tumor latency or growth Female F 1 crossed mice (litter of PyMT ?/-9 Brms1 tg/wt ) were compared for analysis of tumor and metastasis development. As previously demonstrated [25, 26] , all mice expressing the PyMT oncogene developed mammary carcinoma in multiple (sometimes all 10) mammary glands. (Fig. 2a, b) . All mice Fig. 1 Brms1 expression is increased in transgenic mice. Two-step RT-qPCR using SYBRGreen was utilized to detect Brms1 in normal mouse tissues. Relative expression is graphed as fold change compared to wild-type control. All samples were normalized to ribosomal 18S RNA. a Relative expression of Brms1 in normal mammary gland tissue from wild-type (Brms1 wt ), mammary-selective (Brms1 MMTV ; P = 0.31), and ubiquitous Brms1 mice (Brms1 Ubqs ; P = 0.01). b Relative expression of Brms1 in normal lung from wildtype (Brms1 wt ), mammary-selective (Brms1 MMTV ; P = 0.04), and ubiquitous Brms1 mice (Brms1 Ubqs ; P = 0.02). Statistical analysis was performed using student's two sample t test assuming equal variance. Error bars standard error of the mean for biological replicates (triplicate) developed palpable tumors at approximately 12-14 weeks of age. There were no differences in tumor or lung pathology when comparing controls to either Brms1 over-expressing mice (Supplemental Fig. 1 ). Analysis of primary mammary tumors isolated from PyMT ?/-
/Brms1
Ubqs or PyMT
MMTV revealed increased Brms1 expression in tumors from transgenic mice compared to tumors from PyMT ?/-/ Brms1 wt controls (Fig. 2c, d ). There were no significant differences in the total primary tumor burden per mouse (i.e. mass of all mammary tumors combined) when comparing PyMT
Ubqs or PyMT ?/-/Brms1 MMTV mice with respective controls (Fig. 2e, f 
wt . All samples were normalized to ribosomal 18S RNA. Error bars standard error of the mean for biological replicates (triplicate). e and f Tumors were removed and collectively weighed to determine overall tumor burden. Graphs average total tumor mass per group. Statistical analysis using two-sample student's t test revealed no significant differences in total primary tumor burden per mouse when comparing transgenic PyMT ?/-/Brms1 
wt controls. The median number of metastases was higher in the control mice (median = 31) compared to the Brms1 Ubqs mice (median = 8; P = 0.06) (Fig. 3b, c ; Table 1 ). Subsequently, Brms1
Ubqs mice had significantly fewer metastases at necropsy in a multivariable analysis controlling for total tumor burden and age at necropsy (P \ 0.0001). H&E stained lung sections revealed no gross morphological differences when comparing metastatic lesions from Brms1
Ubqs and control mice (Supplemental Fig. 1 ). As in the control mice, PyMT 
Ubqs mice had no macroscopic nor microscopic metastases in liver, spleen, or kidney (Supplemental Fig. 2 ). There were no differences in the size of metastatic lesions in the lungs of PyMT
Ubqs when compared to respective control mice. To determine whether metastasis suppression was related to alterations that occurred in the primary tumor, proliferation, apoptosis and microvascular density were measured. No significant changes were found (Fig. 4a-c) .
Ubiquitous Brms1 expression induces apoptosis in lung metastases
Apoptosis was analyzed by TUNEL staining to determine whether ubiquitous expression of Brms1 altered apoptosis within metastatic lung lesions. Metastatic foci from PyMT ?/-/Brms1 Ubqs mice exhibited a 3-fold higher apoptosis compared to PyMT ?/-/Brms1 wt littermates (Fig. 5a, c) (Fig. 5b) .
Discussion
For decades, researchers have sought to fully understand the genetic complexities involved in the development and progression of breast carcinoma, including how the hosttumor interactions can potentiate or inhibit tumor progression. Understanding how tumor cells adapt to changing environments, including their ability to survive and proliferate in foreign tissues (i.e. ectopic sites), is important for identification of relevant targets for metastatic disease. These are the first studies to reveal that Brms1 function, as an important mediator of apoptosis and metastasis, may be context-dependent and rely on specific cell-type expression. Consistent with the definition of a metastasis suppressor, Brms1 over-expression did not discernibly affect primary tumor incidence or growth. When expressed ubiquitously, Brms1 suppressed metastasis and induced apoptosis when tumor cells seeded the lungs. The pro-apoptotic effect occurred independently of angiogenic properties and was not reflected in similar analyses of corresponding primary tumors. However, it had been previously shown that BRMS1 could potentiate apoptosis in vitro, sensitize tumor There is a known tendency for the mice to reduce aggressiveness if bred for prolonged times. We observed this during the Brms1 MMTV crosses. Therefore, MMTV-PyMT mice were re-derived by the supplier and purchased by us for the Brms1
Ubqs crosses. This is why there is an apparent increase in basal metastatic potential cells to anoikis in vivo, and correlate with expression of pro-apoptotic genes in clinical samples of breast cancer patients [15, 17, 30] . The data presented in this report suggest that BRMS1 over-expression within the microenvironment where metastases form (i.e. lung parenchyma) could be just as important for induction of tumor cell apoptosis. In support of this notion, several studies have reported that conditioned media from cultured normal lung fragments induced anti-apoptotic signaling [31] or increased the survival of metastatic mammary carcinoma cells [32] , implying that the lung microenvironment can facilitate tumor cell survival. Over-expression of Brms1 in certain environments may reverse those effects. However, the situation may be more complex and depend on specific cell-type expression since Brms1 was also over-expressed in the lungs of Brms1 MMTV mice. Taken together, our findings suggest a potential role for stromal Brms1 expression as a modulator of metastasis. Inhibition of stromal cell signaling appears to be essential for suppression of metastasis by PyMT-derived tumors which rely, in part, on stromal-associated promotion of tumor cell migration, invasion, and metastasis [33] [34] [35] [36] [37] . The MMTV promoter (utilized in PyMT and Brms1 MMTV mice) drives expression within epithelial cells whereas the CMV-enhanced chicken b-actin promoter (utilized in Brms1
Ubqs mice) drives expression in both stromal and epithelial cells). Because MMTV-induced Brms1 expression neither suppressed metastasis nor induced apoptosis within metastatic lesions, it appears that Brms1 expression within both stromal and epithelial cells is necessary for both phenotypes. But, additional studies will be necessary to test this hypothesis directly.
It remains unclear why Brms1 expression in mammary epithelium was not sufficient for metastasis suppression. Prior investigations utilizing xenograft and syngeneic models involved restoration of BRMS1 expression in metastatic cells, i.e. cells which have already overcome outstanding limitations in progression. The autochthonous models utilized here include initiation and progression of mammary carcinomas in a continuously evolving tumor microenvironment and constitutively expressed PyMT and Brms1. Although the findings reported here seemingly contradict transfection and over-expression data, one must consider the dynamics of mammary stromal-epithelial interactions that occur throughout mammary carcinoma progression [38] . The stroma regulates mammary epithelial growth, glandular development and homeostasis. Upon transformation and disease progression, tumor cells bypass stromal regulation and recruit new stromal constituents that modulate the microenvironment to support continuous growth and development [39] . While tumor-stromal interactions are undoubtedly relevant in the injection models, the developmental time line is attenuated and does not fully recapitulate the impact of an evolving microenvironment 
/Brms1
Ubqs exhibited fewer metastases when compared to controls, PyMT ?/-/Brms1 wt . Poisson regression controlling for age and total tumor burden at necropsy revealed a significant reduction in PyMT ?/-/Brms1 Ubqs mice (P \ 0.0001 Ubqs tumors), which have a greater proportion of epithelium-derived cells compared to the normal mammary gland and which is consistent with the MMTV promoter being expressed only in the epithelial compartment. Perhaps a spatiotemporal (before oncogenesis and throughout progression) or a threshold level of BRMS1 expression is required to suppress metastasis. Generating a panel of mice 
Ubqs (n = 6) normalized to control mice, PyMT ?/-/Brms1 wt (n = 9). Statistical analysis using two-sample student's t test revealed no significant change (P = 0.97). Error bars standard error of the mean for biological replicates. c Graph percentage of CD31-stained cells in primary mammary tumors from PyMT ?/-
Ubqs (n = 7) normalized to control mice, PyMT ?/-/Brms1 wt (n = 12). iMVD was determined by averaging the number of CD31-positive vessels in designated ''hot spots''. A minimum of three ''hot spots'' were counted per sample. Statistical analysis using two-sample student's t test revealed no significant change (P = 0.25). Error bars standard error of the mean for biological replicates Ubqs (n = 5) mice normalized to control mice, PyMT ?/-/Brms1 wt (n = 9). Statistical analysis using two-sample student's t test revealed a significant increase in apoptosis in lung metastases of PyMT ?/-/ Brms1
Ubqs mice (P = 0.02). b Graph average percentage of TUNELstained cells in lung metastases in PyMT ?/-/Brms1 MMTV mice (n = 6) normalized to control mice, PyMT ?/-/Brms1 wt (n = 8). Statistical analysis using two-sample student's t test revealed no significant change in apoptosis (P = 0.79). c Representative images of apoptotic bodies in metastases of PyMT with a range of Brms1 expression under temporal control would need to be done in order to evaluate this possibility, but is beyond the scope of this initial report. Host genetic background is another important factor involved in the development of mammary carcinoma metastasis [40, 41] . The data presented here represent the F 1 generation of the PyMT oncogene on an FVB strain crossed with the Brms1 transgene on the C57BL/6 strain. This is important because Hunter and colleagues showed that the F 1 generation MMTV-PyMT 9 C57BL/6 cross were metastasis suppressed [40, 41] . When this project began, congenic MMTV-PyMT on a C57BL/6 background did not exist. They recently became available, allowing assessment of the impact of Brms1 over-expression on MMTV-PyMT independent of background genetic complications. We have initiated these studies but require larger numbers of animals before we can accurately assess or interpret the findings.
Our results provide a potential explanation for inconsistencies reported for BRMS1 mRNA and protein expression in clinical samples [42] [43] [44] [45] [46] . Interpretation of the clinical studies is affected by the purity of sample (i.e. contamination by stromal cells), discordance between mRNA and BRMS1 protein levels and BRMS1 localization in the nucleus versus cytoplasm. The finding that Brms1-mediated metastasis suppression may be influenced by expression within the stromal compartment strongly suggests that expression in specific cell types may be more important than expression within primary tumor cells as an indicator of metastatic disease than previously appreciated.
